Moreover, TCL1b structure-based inhibitor, namely ‘TCL1b-Akt-in', efficiently inhibited platelet-derived growth factor (PDGF)-stimulated Akt kinase activity, which, in turn, inhibited cellular proliferation of angiosarcoma and reticulum cell sarcoma. The gene discussed is AKT1; the disease is reticulum cell sarcoma.